Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-09
2008-09-09
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S193000
Reexamination Certificate
active
10509770
ABSTRACT:
The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1is C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, substituted C3-C7cycloalkyl, C3-C7cycloalkyl-C1-C3alkyl, substituted C3-C7cycloalkyl-C1-C3alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2is hydrogen, C1-C3alkyl, C3-C6cycloalkyl-C1-C3alkyl, or a group of formula IIR3is hydrogen or C1-C3alkyl;R4is hydrogen, halo, or C1-C3alkyl;R5is hydrogen or C1-C3alkyl;R6is hydrogen or C1-C6alkyl; andn is an integer from 1 to 6 inclusively.The compounds of the present invention are useful for activating 5-HT1Freceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
REFERENCES:
patent: 5521196 (1996-05-01), Audia et al.
patent: 5521197 (1996-05-01), Audia
patent: 5698571 (1997-12-01), Audia et al.
patent: 5708187 (1998-01-01), Flaugh et al.
patent: 5721252 (1998-02-01), Audia et al.
patent: 5814653 (1998-09-01), Flaugh et al.
patent: 5817671 (1998-10-01), Filla et al.
patent: 6650463 (2003-11-01), Obikawa et al.
patent: 6777428 (2004-08-01), Krushinski et al.
patent: 2006/0211734 (2006-09-01), Blanco-Pillado et al.
patent: WO 96 29075 (1996-09-01), None
patent: WO 97 13512 (1997-04-01), None
patent: WO 98 08502 (1998-03-01), None
patent: WO 98 15545 (1998-04-01), None
patent: WO 98 20875 (1998-05-01), None
patent: WO 98 46570 (1998-10-01), None
patent: WO 98 55115 (1998-12-01), None
patent: WO 99 25348 (1999-05-01), None
patent: WO 00 00487 (2000-01-01), None
patent: WO 00 00490 (2000-01-01), None
patent: WO 00 34266 (2000-06-01), None
patent: WO 00 47559 (2000-08-01), None
patent: WO 00 50426 (2000-08-01), None
patent: WO 03/000245 (2003-01-01), None
Phebus et al. “Characterization of LY344864 . . . ” CA 128:18603 (1997).
Radl et al. “Synthesis and antinociceptive . . . ” CA 130:352171 (1999).
King “Medicinal chemistry: proinceples and practice” p. 206-209 (1994).
Nika Adham, et al, Proc. Natl. Acad. Sci. USA, vol. 9, pp. 408-412, Jan. 1993 Neurobiology.
Japanese Abstract for JP 03255426 (Nov. 14, 1991), Toshiba Corp., Japan.
Cohen Michael Philip
Kohlman Daniel Timothy
Liang Sidney Xi
Mancuso Vincent
Victor Frantz
Chang Celia
Eli Lilly and Company
Elrifi Ivor R.
Erlacher Heidi A.
LandOfFree
Pyridinoylpiperidines as 5-HT 1F agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridinoylpiperidines as 5-HT 1F agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridinoylpiperidines as 5-HT 1F agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3905235